Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EmLiFa: Empagliflozin for Liver Fat in T2D
NCT02637973Phase 4Completed
- Sponsor
- German Diabetes Center
- Start
- Dec 2015
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of empagliflozin in type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease (NAFLD), sponsored by German Diabetes Center. Started Dec 2015; status: completed.
02
Drugs
empagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT02637973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02637973.